Clinical Trial Update: Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating an anti-tenascin radiolabeled antibody therapy for glioblastoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Anti-tenascin radiolabeled antibody therapy

Snippet

Sponsor: Bradmer Pharmaceuticals Inc. | Conditions: Glioblastoma Multiforme | Phase 3 | Status: TERMINATED